Glutathione and glutathione peroxidase expression in breast cancer: An immunohistochemical and molecular study

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1119-1128

  Jardim, Bruna Victorasso ^a,b   Moschetta, Marina Gobbe ^b   Leonel, Camila ^a,b   Gelaleti, Gabriela Bottaro ^a,b   Regiani, Vitor Rafael ^b   Ferreira, Livia Carvalho ^a,b   Lopes, Juliana Ramos ^a,b   De Campos Zuccari, Debora Ap Pires ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

Chemotherapy; Glutathione; Immunohistochemistry; Prognosis; Real time PCR

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE SYNTHASE; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER MORTALITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84880592778     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2540     Document Type: Article

References (36)

1. Gonzalez-Angulo AM, Moraes-Vasquez F and Hortobagyl GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
2. Instituto Nacional do Câncer (INCA), Estimativas da incidência e mortalidade por câncer no Brasil. Ministério da Saúde Rio de Janeiro. http://www.inca.gov.br/estimativa/2010/index.asp? link=conteudo-view.asp&ID=5. Accessed Nov. 20, 2011.
3. Gralow J, Ozols RF, Bajorin DF, et al: Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 26: 313-325, 2008.
4. Hicks DG and Kulkarni S: Trastuzumab as adjuvant therapy for early breast cancer. Arch Pathol Lab Med 132: 1008-1015, 2008.
5. vant't Veer LJ, Paik S and Hayes DF: Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23: 1631-1635, 2005.
6. Pedersen L, Gunnarsdottir KA, Rasmussen BB, et al: The prognostic influence of multifocality in breast cancer patients. Breast 13: 188-193, 2004.
7. Duffy MJ and Crown J: A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54: 1770-1779, 2008.
8. Thomas E and Berner G: Prognostic and predictive implications of HER2 status for breast cancer patients. Eur J Oncol Nurs 4: 10-17, 2000.
9. Duffy MJ, O'Donovan N and Crown J: Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 37: 151-159, 2011.
10. Pastore A, Federici G, Bertini E and Piemonte F: Analysis of glutathione: implication in redox and detoxification. Clin Chem Acta 333: 19-39, 2003.
11. Townsend DM and Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375, 2003.
12. Jardim BV, Moschetta MG, Gelaleti GB, et al: Glutathione transferase pi (GSTpi) expression in breast cancer: An immunohistochemical and molecular study. Acta Histochem 114: 510-517, 2012.
13. Huber PC, Almeida WP and Fatima A: Glutationa e enzimas relacionadas: papel biológico e importância em processos patológicos. Quím Nova 31: 1170-1179, 2008.
14. Carnicer MJ, Bernardini S, Bellincampi L, et al: Role of γ-glutamyl cysteine synthetase (γ-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias. Clin Chem Acta 365: 342-345, 2006.
15. Uchida M, Sugaya M, Kanamaru T and Hisatomi H: Alternative RNA splicing in expression of the glutathione synthetase gene in human cells. Mol Biol Rep 37: 2105-2109, 2010.
16. Valko M, Leibfritz D, Moncol J, et al: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
17. Ballatori N, Krance SM, Notenboom S, et al: Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390: 191-214, 2009.
18. Kumaraguruparan R, Balachandran C, Manohar BM and Nagini S: Altered oxidant-antioxidant profile in canine mammary tumours. Vet Res Commun 29: 287-296, 2005.
19. Rajneesh CP, Manimaran A, Sasikala KR and Adaikappan P: Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J 49: 640-643, 2008.
20. Kasapović J, Pejić S, Stojiljković V, et al: Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide. Clin Biochem 43: 1287-1293, 2010.
21. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784-2795, 2010.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) method. Methods 25: 402-408, 2001.
23. Yeh CC, Hou MF, Wu SH, et al: A study of glutathione status in the blood and tissues of patients with breast cancer. Cell Biochem Funct 24: 555-559, 2006.
24. Kasapović J, Pejić S, Todorović A, et al: Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct 26: 723-730, 2008.
25. Fernandes RC, Bevilacqua JL, Soares IC, et al: Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 55: 346-352, 2009.
26. Basu S, Chen W, Tchou J, et al: Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112: 995-1000, 2008.
27. Murawaki Y, Tsuchiya H, Kanbe T, et al: Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 259: 218-230, 2008.
28. Li S, Yan T, Yang JQ, et al: The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase. Cancer Res 60: 3927-3939, 2000.
29. Estrela JM, Ortega A and Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181, 2006.
30. Gaudiano G, Koch TH, LoBello M, et al: Lack of glutathione conjugation to adriamycin in human breast cancer MCF-7/DOX cells. Inhibition of glutathione S-transferase p1-1 by glutathione conjugates from anthracyclines. Biochem Pharmacol 60: 1915-1923, 2000.
31. Ozkan A and Fiskin K: Protective effect of antioxidant enzymes against drug cytotoxicity in MCF-7 cells. Exp Oncol 28: 86-88, 2006.
32. Ilvasova D, Mixon G, Wang F, et al: Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. Biomarkers 14: 321-325, 2009.
33. Han XQ, Li ZH, Zhang JG, et al: Effect of decreased GSH on sensitivity of breast cancer cells to ADM. Sichuan Da Xue Xue Bao Yi Xue Ban 36: 770-774, 2007 (In Chinese).
34. Vibet S, Goupille C, Bougnoux P, et al: Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44: 1483-1491, 2008.
35. Sun W, Kalen AL, Smith BJ, et al: Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res 69: 4294-4300, 2009.
36. Di X, Shiu RP, Newsham IF and Gewirtz DA: Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to adriamycin. Biochem Pharmacol 77: 1139-1150, 2009.